The study, conducted at a hospital in Spain from 2015 to 2017, included all 100 patients who were switched to the biosimilar from the reference infliximab when the hospital transitioned to using the lower-cost product.
While it is becoming more common to switch patients with inflammatory bowel disease (IBD) to biosimilar CT-P13 (Inflectra, Remsima) from the reference infliximab (Remicade), long-term follow-up data is lacking. However, in one newly published study from a single-center, researchers reported that, at 2 years, most patients who switched continued on the biosimilar.
The study, conducted at a hospital in Spain from 2015 to 2017, included all 100 patients with moderate to severe Crohn disease (CD) (n = 64) or ulcerative colitis (UC) (n = 36) who were switched to the biosimilar from the reference infliximab when the hospital transitioned to using the lower-cost biosimilar.
The study’s primary end point was to analyze loss of response to infliximab after the switch.
The investigators found that, at 2 years, 72% of patients remained on the biosimilar. In total, 15% discontinued after loss of response, 4% discontinued due to adverse events (AEs), and 8% discontinued due to remission. One patient who achieved remission was switched to a different biologic after developing episcleritis. A total of 22% of patients required dose escalation during the follow-up period.
At the beginning of the study, 78% of patients were in remission. At 12, 18, and 24 months, 69.6%, 69.9%, and 68.5%, respectively, remained in remission. Among those who lost response, there was a median time to discontinuation of 15 months (range, 8-24).
By disease type, at 2 years, 25% of the patients with CD had discontinued (10 for loss of response, 3 because of clinical remission, 2 because of AEs, and 1 because of another medical indication). In the UC group, 33.33% of patients had discontinued at 2 years (5 for loss of response, 5 because of remission, and 2 because of AEs).
A total of 14% of patients experienced AEs, which included skin reactions, asthenia, headache, paresthesia during infusion, and other AEs. Six patients were admitted to the hospital for AEs.
Two patients, both in the CD group, developed antidrug antibodies over 18 months of follow-up. One of these patients achieved remission and discontinued treatment, while the other switched to adalimumab.
According to the authors, this study demonstrates the long-term efficacy of CT-P13 after a switch, and they add that the tranistion to the biosimilar saved the healthcare system €3000 (US $3379.50) per patient per year.
Reference
Veloz MFG, Jiménex MB, Delgado TV, et al. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data [published online June 18, 2019]. Therap Adv Gastroenterol. doi: 10.1177/1756284819858052.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.
Physicians Agree on Safety of Biosimilars, Nonmedical Switching in IBD, Survey Says
November 2nd 2023An international survey found that providers agree that use of biosimilars in inflammatory bowel disease (IBD) is safe and effective in both patients who are treatment-naïve and those who are already being treated with a reference agent.